Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial

Ming Sheng Zhou, Ivonne Hernandez Schulman

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


A growing number of experimental and clinical studies have provided evidence indicating that pharmacological blockade of the renin-angiotensin system (RAS) by either angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers reduces the incidence of new onset type 2 diabetes in subjects with hypertension and/or cardiovascular disease, independently of antihypertensive and cardiovascular protective effects. The beneficial effects of RAS inhibition on the development of diabetes have been largely attributed to improvements in peripheral insulin sensitivity and glucose metabolism. This review focuses on recent experimental and clinical evidence supporting the role of RAS inhibition in the reduction of new onset type 2 diabetes and the mechanisms that may be involved.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalVascular Health and Risk Management
StatePublished - 2009


  • Antihypertensive
  • Diabetes
  • Renin-angiotensin system

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial'. Together they form a unique fingerprint.

Cite this